Anita Zahlten‐Kumeli

Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study

Meletios Α. Dimopoulos, Hang Quach, María‐Victoria Mateos et al. · The Lancet · 2020 · 422 citations

Medicine, Pharmacology, Pharmacotherapy +14

Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial

Meletios Α. Dimopoulos, Hartmut Goldschmidt, Rubén Niesvizky et al. · The Lancet Oncology · 2017 · 401 citations

Medicine, Oncology, Pharmacology +14

Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study

Philippe Moreau, María‐Victoria Mateos, James R. Berenson et al. · The Lancet Oncology · 2018 · 206 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +14

Carfilzomib or bortezomib with melphalan-prednisone for transplant-ineligible patients with newly diagnosed multiple myeloma

Thierry Façon, Jae Hoon Lee, Philippe Moreau et al. · Blood · 2019 · 130 citations · Full text

Medicine, Hematology, Pharmacotherapy +14

Bemarituzumab as first-line treatment for locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma: final analysis of the randomized phase 2 FIGHT trial

Zev A. Wainberg, Yoon‐Koo Kang, Keun‐Wook Lee et al. · Gastric Cancer · 2024 · 68 citations · Full text

Medicine, Oncology, Pharmacology +16